STOCK TITAN

Nantahala discloses 9.99% Grace Therapeutics (NASDAQ: GRCE) stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Grace Therapeutics, Inc. reported an updated large shareholder position in this amended Schedule 13G. Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, may be deemed to beneficially own 1,586,659 shares of common stock, or 9.99% of the class as of December 31, 2025.

This amount includes 408,456 shares that can be acquired within sixty days through warrant exercises. The reporting persons share voting and dispositive power over these shares, and certify that the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Grace Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:02/13/2026
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:02/13/2026
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:02/13/2026
Grace Therapeutics, Inc

NASDAQ:GRCE

GRCE Rankings

GRCE Latest News

GRCE Latest SEC Filings

GRCE Stock Data

55.86M
10.62M
30.28%
27.64%
0.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON